Ebolaviruses associated with differential pathogenicity induce distinct host responses in human macrophages

Journal of Virology

Volumn 91, Issue 11, 2017, Pages

  Olejnik, Judith ^a,b   Forero, Adriana ^c   Deflubé, Laure R ^a,b   Hume, Adam J ^a,b   Manhart, Whitney A ^a,b   Nishida, Andrew ^c   Marzi, Andrea ^d   Katze, Michael G ^c   Ebihara, Hideki ^d,e   Rasmussen, Angela L ^c,f   Mühlberger, Elke ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e MAYO CLINIC   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Chemokines; Cytokines; Ebola virus; Filovirus; Host response; Interferons; Macrophages; Reston virus; Toll like receptor 4; Toll like receptors

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 3; TOLL LIKE RECEPTOR 4; CHEMOKINE; CYTOKINE; IRF3 PROTEIN, HUMAN; NFKB1 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE STORM; EBOLAVIRUS; FILOVIRUS INFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RESTON VIRUS; SIGNAL TRANSDUCTION; VIRUS LIKE AGENT; VIRUS VIRULENCE; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; DENDRITIC CELL; GENE EXPRESSION PROFILING; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VERO CELL LINE; VIROLOGY; VIRULENCE;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; EBOLAVIRUS; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERONS; MACROPHAGES; NF-KAPPA B P50 SUBUNIT; TOLL-LIKE RECEPTOR 4; VERO CELLS; VIRULENCE;

EID: 85019232385     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00179-17     Document Type: Article

References (80)

1. Rougeron V, Feldmann H, Grard G, Becker S, Leroy EM. 2015. Ebola and Marburg haemorrhagic fever. J Clin Virol 64:111-119. https://doi.org/10.1016/j.jcv.2015.01.014.
2. McElroy AK, Harmon JR, Flietstra TD, Campbell S, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Kratochvil CJ, Iwen PC, Smith PW, Ahmed R, Nichol ST, Spiropoulou CF. 27 June 2016. Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. Clin Infect Dis https://doi.org/10.1093/cid/ciw334.
3. Ruibal P, Oestereich L, Lüdtke A, Becker-Ziaja B, Wozniak DM, Kerber R, Korva M, Cabeza-Cabrerizo M, Bore JA, Koundouno FR, Duraffour S, Weller R, Thorenz A, Cimini E, Viola D, Agrati C, Repits J, Afrough B, Cowley LA, Ngabo D, Hinzmann J, Mertens M, Vitoriano I, Logue CH, Boettcher JP, Pallasch E, Sachse A, Bah A, Nitzsche K, Kuisma E, Michel J, Holm T, Zekeng E-G, García-Dorival I, Wölfel R, Stoecker K, Fleischmann E, Strecker T, Di Caro A, Avšič-Županc T, Kurth A, Meschi S, Mély S, Newman E, Bocquin A, Kis Z, Kelterbaum A, Molkenthin P, Carletti F, Portmann J, Wolff S, Castilletti C, Schudt G, Fizet A, Ottowell LJ, Herker E, Jacobs T, Kretschmer B, Severi E, Ouedraogo N, Lago M, Negredo A, Franco L, Anda P, Schmiedel S, Kreuels B, Wichmann D, Addo MM, Lohse AW, De Clerck H, Nanclares C, Jonckheere S, Van Herp M, Sprecher A, Xiaojiang G, Carrington M, Miranda O, Castro CM, Gabriel M, Drury P, Formenty P, Diallo B, Koivogui L, Magassouba N, Carroll MW, Günther S, Muñoz-Fontela C. 2016. Unique human immune signature of Ebola virus disease in Guinea. Nature 533:100-104. https://doi.org/10.1038/nature17949.
4. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ. 1999. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179(Suppl):S188-S191.
5. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P, Fisher-Hoch SP, McCormick JB, Georges AJ, Debre P. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5:423-426. https://doi.org/10.1038/7422.
6. Gupta M, Mahanty S, Ahmed R, Rollin PE. 2001. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-ICinduced IFN-alpha in vitro. Virology 284:20-25. https://doi.org/10.1006/viro.2001.0836.
7. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. 2001. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 124:453-460. https://doi.org/10.1046/j.1365-2249.2001.01517.x.
8. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. 2010. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 4(10): e837. https://doi.org/10.1371/journal.pntd.0000837.
9. Bixler S, Goff A. 2015. The role of cytokines and chemokines in filovirus infection. Viruses 7:5489-5507. https://doi.org/10.3390/v7102892.
10. Miranda MEG, Miranda NLJ. 2011. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 204(Suppl):S757-S760.
11. Fisher-Hoch SP, Brammer TL, Trappier SG, Hutwagner LC, Farrar BB, Ruo SL, Brown BG, Hermann LM, Perez-Oronoz GI, Goldsmith CS, Hanes MA, McCormick JB. 1992. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 166:753-763. https://doi.org/10.1093/infdis/166.4.753.
12. Geisbert TW, Strong JE, Feldmann H. 2015. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis 212(Suppl):S91-S97.
13. Groseth A, Marzi A, Hoenen T, Herwig A, Gardner D, Becker S, Ebihara H, Feldmann H. 2012. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog 8:e1002847. https://doi.org/10.1371/journal.ppat.1002847.
14. Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM. 2015. Interferon α/β receptor-deficient mice as a model for Ebola virus disease. J Infect Dis 212(Suppl 2):S282-S294. https://doi.org/10.1093/infdis/jiv215.
15. de Wit E, Munster VJ, Metwally SA, Feldmann H. 2011. Assessment of rodents as animal models for Reston ebolavirus. J Infect Dis 204(Suppl): S968-S972. https://doi.org/10.1093/infdis/jir330.
16. Raymond J, Bradfute S, Bray M. 2011. Filovirus infection of STAT-1 knockout mice. J Infect Dis 204(Suppl):S986-S990.
17. Messaoudi I, Amarasinghe GK, Basler CF. 2015. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol 13:663-676. https://doi.org/10.1038/nrmicro3524.
18. Rasmussen AL. 2016. Host factors in Ebola infection. Annu Rev Genomics Hum Genet 17:333-351. https://doi.org/10.1146/annurev-genom-083115-022446.
19. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, Garcia-Sastre A, Mühlberger E, García-Sastre A. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77:7945-7956. https://doi.org/10.1128/JVI.77.14.7945-7956.2003.
20. Reid SP, Valmas C, Martinez O, Sanchez FM, Basler CF. 2007. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 81:13469-13477.
21. Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF, Amarasinghe GK. 2010. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 17:165-172. https://doi.org/10.1038/nsmb.1765.
22. Kimberlin CR, Bornholdt ZA, Li S, Woods VL, MacRae IJ, Saphire EO. 2010. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci U S A 107:314-319. https://doi.org/10.1073/pnas.0910547107.
23. Guito JC, Albariño CG, Chakrabarti AK, Towner JS. 2017. Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system. Virology 501:147-165. https://doi.org/10.1016/j.virol.2016.11.015.
24. Schwarz TM, Edwards MR, Diederichs A, Alinger JB, Leung DW, Amarasinghe GK, Basler CF. 14 December 2016. VP24-karyopherin alpha binding affinities differ between Ebolavirus species influencing interferon inhibition and VP24 stability. J Virol https://doi.org/10.1128/JVI.01715-16.
25. Olejnik J, Ryabchikova E, Corley RB, Mühlberger E. 2011. Intracellular events and cell fate in filovirus infection. Viruses 3:1501-1531. https://doi.org/10.3390/v3081501.
26. Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF. 2013. Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol 87:3801-3814. https://doi.org/10.1128/JVI.02695-12.
27. Ströher U, West E, Bugany H, Klenk H-D, Schnittler H-J, Feldmann H. 2001 Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75:11025-11033. https://doi.org/10.1128/JVI.75.22.11025-11033.2001.
28. Hensley LE, Young HA, Jahrling PB, Geisbert TW. 2002. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80:169-179. https://doi.org/10.1016/S0165-2478(01)00327-3.
29. Wahl-Jensen V, Kurz S, Feldmann F, Buehler LK, Kindrachuk J, Defilippis V, da Silva Correia J, Früh K, Kuhn JH, Burton DR, Feldmann H. 2011. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis 5:e1359. https://doi.org/10.1371/journal.pntd.0001359.
30. Escudero-Pérez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. 2014 Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog 10:e1004509. https://doi.org/10.1371/journal.ppat.1004509.
31. Wahl-Jensen V, Kurz SK, Hazelton PR, Schnittler HJ, Stroher U, Burton DR, Feldmann H. 2005. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 79: 2413-2419. https://doi.org/10.1128/JVI.79.4.2413-2419.2005.
32. Okumura A, Pitha PM, Yoshimura A, Harty RN. 2010. Interaction between Ebola virus glycoprotein and host Toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol 84:27-33. https://doi.org/10.1128/JVI.01462-09.
33. Okumura A, Rasmussen AL, Halfmann P, Feldmann F, Yoshimura A, Feldmann H, Kawaoka Y, Harty RN, Katze MG. 2015. Suppressor of cytokine signaling 3 is an inducible host factor that regulates virus egress during Ebola virus infection. J Virol 89:10399-10406. https://doi.org/10.1128/JVI.01736-15.
34. Zhao D, Han X, Zheng X, Wang H, Yang Z, Liu D, Han K, Liu J, Wang X, Yang W, Dong Q, Yang S, Xia X, Tang L, He F. 2016. The myeloid LSECtin is a DAP12-coupled receptor that is crucial for inflammatory response induced by Ebola virus glycoprotein. PLoS Pathog 12:e1005487. https://doi.org/10.1371/journal.ppat.1005487.
35. Baize S, Leroy EM, Georges AJ, Georges-Courbot M-CC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E. 2002. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128:163-168. https://doi.org/10.1046/j.1365-2249.2002.01800.x.
36. Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6:644-658. https://doi.org/10.1038/nri1900.
37. Nelson EV, Schmidt KM, Deflubé LR, Doğanay S, Banadyga L, Olejnik J, Hume AJ, Ryabchikova E, Ebihara H, Kedersha N, Ha T, Mühlberger E. 2016 Ebola virus does not induce stress granule formation during infection and sequesters stress granule proteins within viral inclusions. J Virol 90:7268-7284. https://doi.org/10.1128/JVI.00459-16.
38. Hoenen T, Shabman RS, Groseth A, Herwig A, Weber M, Schudt G, Dolnik O, Basler CF, Becker S, Feldmann H. 2012. Inclusion bodies are a site of ebolavirus replication. J Virol 86:11779-11788. https://doi.org/10.1128/JVI.01525-12.
39. Lawrence T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1(6):a001651. https://doi.org/10.1101/cshperspect.a001651.
40. Boehmann Y, Enterlein S, Randolf A, Mühlberger E. 2005. A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology 332:406-417. https://doi.org/10.1016/j.virol.2004.11.018.
41. Kash JC, Mu E, Carter V, Grosch M, Perwitasari O, Proll SC, Thomas MJ, Weber F, Klenk HD, Katze MG, Muhlberger E, Mühlberger E. 2006. Global suppression of the host antiviral response by Ebola-and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 80:3009-3020. https://doi.org/10.1128/JVI.80.6.3009-3020.2006.
42. Alfson KJ, Avena LE, Beadles MW, Staples H, Nunneley JW, Ticer A, Dick EJ, Owston MA, Reed C, Patterson JL, Carrion R, Griffiths A. 2015. Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J Virol 89:6773-6781. https://doi.org/10.1128/JVI.00649-15.
43. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CRH. 1991. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 266:19490-19498.
44. Kutuzova GD, Albrecht RM, Erickson CM, Qureshi N. 2001. Diphosphoryl lipid A from Rhodobacter sphaeroides blocks the binding and internalization of lipopolysaccharide in RAW 264.7 cells. J Immunol 167: 482-489. https://doi.org/10.4049/jimmunol.167.1.482.
45. Hartman AL, Ling L, Nichol ST, Hibberd ML. 2008. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 82:5348-5358. https://doi.org/10.1128/JVI.00215-08.
46. Melchjorsen J. 2013. Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity-clues for treatments and vaccines. Viruses 5:470-527. https://doi.org/10.3390/v5020470.
47. Boehme KW, Compton T. 2004. Innate sensing of viruses by Toll-like receptors. J Virol 78:7867-7873. https://doi.org/10.1128/JVI.78.15.7867-7873.2004.
48. Georgel P, Jiang Z, Kunz S, Janssen E, Mols J, Hoebe K, Bahram S, Oldstone MBA, Beutler B. 2007. Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 362:304-313. https://doi.org/10.1016/j.virol.2006.12.032.
49. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1:398-401. https://doi.org/10.1038/80833.
50. Rallabhandi P, Phillips RL, Boukhvalova MS, Pletneva LM, Shirey KA, Gioannini TL, Weiss JP, Chow JC, Hawkins LD, Vogel SN, Blanco JCG. 2012 Respiratory syncytial virus fusion protein-induced Toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2. mBio 3:e00218-12. https://doi.org/10.1128/mBio.00218-12.
51. Lu Y-C, Yeh W-C, Ohashi PS. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42:145-151. https://doi.org/10.1016/j.cyto.2008.01.006.
52. Kim HM, Park BS, Kim J-I, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee J-O. 2007. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130:906-917. https://doi.org/10.1016/j.cell.2007.08.002.
53. Park BS, Song DH, Kim HM, Choi B-S, Lee H, Lee J-O. 2009. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458:1191-1195. https://doi.org/10.1038/nature07830.
54. Dominguez-Soto A, Aragoneses-Fenoll L, Martin-Gayo E, Martinez-Prats L, Colmenares M, Naranjo-Gomez M, Borras FE, Munoz P, Zubiaur M, Toribio ML, Delgado R, Corbi AL. 2007. The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells. Blood 109:5337-5345. https://doi.org/10.1182/blood-2006-09-048058.
55. Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, Hume DA, Stacey KJ, Young PR. 2015. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med 7:304ra142. https://doi.org/10.1126/scitranslmed.aaa3863.
56. Rialdi A, Campisi L, Zhao N, Lagda AC, Pietzsch C, Ho JSY, Martinez-Gil L, Fenouil R, Chen X, Edwards M, Metreveli G, Jordan S, Peralta Z, Munoz-Fontela C, Bouvier N, Merad M, Jin J, Weirauch M, Heinz S, Benner C, van Bakel H, Basler C, Garcia-Sastre A, Bukreyev A, Marazzi I. 2016. Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science 352:aad7993. https://doi.org/10.1126/science.aad7993.
57. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem 277:47834-47843. https://doi.org/10.1074/jbc.M207873200.
58. Kagan JC, Medzhitov R. 2006. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125:943-955. https://doi.org/10.1016/j.cell.2006.03.047.
59. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, Golenbock DT. 2003. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198: 1043-1055. https://doi.org/10.1084/jem.20031023.
60. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S. 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4:1144-1150. https://doi.org/10.1038/ni986.
61. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. 2008. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-γ. Nat Immunol 9:361-368. https://doi.org/10.1038/ni1569.
62. Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Dye JM, Bavari S, Bray M, Ozato K. 2014. Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways. J Interferon Cytokine Res 34(2): 79-89. https://doi.org/10.1089/jir.2013.0035.
63. Mingo RM, Simmons JA, Shoemaker CJ, Nelson EA, Schornberg KL, D'Souza RS, Casanova JE, White JM. 2015. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol 89:2931-2943. https://doi.org/10.1128/JVI.03398-14.
64. Simmons JA, D'Souza RS, Ruas M, Galione A, Casanova JE, White JM. 14 October 2015. The Ebolavirus glycoprotein directs fusion through NPC1+ endolysosomes. J Virol https://doi.org/10.1128/JVI.01828-15.
65. Reimer T, Brcic M, Schweizer M, Jungi TW. 2008. poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J Leukoc Biol 83:1249-1257. https://doi.org/10.1189/jlb.0607412.
66. Solis M, Romieu-Mourez R, Goubau D, Grandvaux N, Mesplede T, Julkunen I, Nardin A, Salcedo M, Hiscott J. 2007. Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages. Eur J Immunol 37: 528-539. https://doi.org/10.1002/eji.200636090.
67. Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, Fang Y, Hall Y, Zekeng E-G, Lüdtke A, Xia D, Kerber R, Krumkamp R, Duraffour S, Sissoko D, Kenny J, Rockliffe N, Williamson ED, Laws TR, N=Faly M, Matthews DA, Günther S, Cossins AR, Sprecher A, Connor JH, Carroll MW, Hiscox JA. 2017. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol 18:4. https://doi.org/10.1186/s13059-016-1137-3.
68. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 1999. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 179(Suppl):S248-S258.
69. Leung DW, Shabman RS, Farahbakhsh M, Prins KC, Borek DM, Wang T, Mühlberger E, Basler CF, Amarasinghe GK. 2010. Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J Mol Biol 399:347-357. https://doi.org/10.1016/j.jmb.2010.04.022.
70. Zhang APP, Bornholdt ZA, Liu T, Abelson DM, Lee DE, Li S, Woods VL, Saphire EO. 2012. The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog 8:e1002550. https://doi.org/10.1371/journal.ppat.1002550.
71. Pappalardo M, Juliá M, Howard MJ, Rossman JS, Michaelis M, Wass MN. 2016 Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses. Sci Rep 6:23743. https://doi.org/10.1038/srep23743.
72. Martins K, Cooper C, Warren T, Wells J, Bell T, Raymond J, Stuthman K, Benko J, Garza N, van Tongeren S, Donnelly G, Retterer C, Dong L, Bavari S. 2015. Characterization of clinical and immunological parameters during ebola virus infection of rhesus macaques. Viral Immunol 28:32-41. https://doi.org/10.1089/vim.2014.0085.
73. Licata JM, Johnson RF, Han Z, Harty RN. 2004. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol 78:7344-7351. https://doi.org/10.1128/JVI.78.14.7344-7351.2004.
74. Kallstrom G, Warfield KL, Swenson DL, Mort S, Panchal RG, Ruthel G, Bavari S, Aman MJ. 2005. Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods 127:1-9. https://doi.org/10.1016/j.jviromet.2005.02.015.
75. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357-359. https://doi.org/10.1038/nmeth.1923.
76. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15-21. https://doi.org/10.1093/bioinformatics/bts635.
77. Anders S, Pyl PT, Huber W. 2015. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166-169. https://doi.org/10.1093/bioinformatics/btu638.
78. Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139-140. https://doi.org/10.1093/bio informatics/btp616.
79. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57: 289-300.
80. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. 1998. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics 14:656-664. https://doi.org/10.1093/bioinformatics/14.8.656.